NCT04839484Unknown不适用
A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of Lumina™ in the Treatment of Nasolabial Folds
LifeSprout, Inc.4 个研究点 分布在 3 个国家目标入组 118 人开始时间: 2021年3月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 118
- 试验地点
- 4
- 主要终点
- primary effectiveness Wrinkle Severity Rating Scale (WSRS)
研究概览
简要总结
The study will be a prospective, randomized, split-face, double blind, controlled, clinical trial to evaluate the safety and effectiveness of Lumina™ for the treatment of Nasolabial Folds (NLFs). Subjects will be randomized to receive treatment (Lumina™) in one NLF and control (Restylane® Defyne) in the contra-lateral NLF. 118 subjects will be treated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Single (Outcomes Assessor)
盲法说明
A blinded evaluator at each site who does not know what patient was treated with what product (per side) scores the patient. Photographic reviewers are also blinded to treatment.
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject aged at least 22 years.
- •Subject has bilateral moderate or severe (grade 3 or 4) NLFs on the WSRS as scored by a live, masked evaluator.
- •Subject willing to abstain from other facial aesthetic procedures in the NLFs through the 12 month (13 month if retreatment at 12 months) follow-up visit which could interfere with treatment outcomes (e.g. facial fillers, skin laser and radiofrequency therapy such as Thermage, chemical re-surfacing, dermabrasion, Botox injections, aesthetic facial surgery, other facial treatments in the NLFs.
- •Subject understands and accepts the obligation to present for all scheduled follow-up visits and is logistically able to meet all study requirements.
- •Subject with facial hair which may obstruct the assessment of the treatment area, must be agreeable with non-laser removal of facial hair prior to assessment visits.
- •Subject willing to provide written informed consent for their participation in the study.
排除标准
- •Subject is a female of childbearing potential (e.g., not postmenopausal for at least one year or has not had a hysterectomy or tubal ligation) not using medically effective birth control (e.g., hormonal methods in use at least 30 days prior to injection or barrier methods such as condom and spermicide in use at least 14 days prior to injection) or is pregnant, lactating, or plans to become pregnant during the study.
- •Subject has participated in a clinical study in which an investigational device or drug was received in the 30 days prior to screening or plans to enroll in such a study during the course of the current study.
- •Subject is an employee or direct relative of an employee of the investigational site or study sponsor.
- •Subject who has received surgery in the NLFs.
- •Subject has a serious or progressive disease, which, in the investigator's judgment, puts the subject at undue risk (e.g. uncontrolled diabetes, autoimmune disease, cardiac pathologies).
- •Subject has an acute inflammatory process or infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events.
- •Subject has a disorder that may impact wound healing such as connective tissue or immunosuppressive disorder.
- •Subject has a history of precancerous lesions/skin malignancies.
- •Subject has had an active skin disease within the past 6 months.
- •Subject has scars, infection, rosacea, herpes, acne, blotches or other pathology in the NLFs.
- •Subject has facial hair covering the nasolabial folds that they are unwilling to remove for study assessments.
- •Subject has a past history of streptococcal disease or an active streptococcus infection.
- •Subject has a past history of allergy or hypersensitivity to gram positive bacterial proteins.
- •Subject is predisposed to keloidosis or hypertrophic scarring.
- •Subject has a known history of hyper- or hypo-pigmentation in the NLFs.
- •Subject with known allergy to poly (ε-caprolactone) microfibers, phosphate buffered saline, polyethylene glycol dithiol (PEG-SH), sodium-hyaluronate of bacterial origin, hyaluronic acid or streptococcal protein.
- •Subject has a known history of multiple allergies, allergic/anaphylactic reactions including hypersensitivity to lidocaine or anesthetics of the amide type.
- •Subject has a known bleeding disorder.
- •Subject has received within the past week or plans to receive up to 1 month after treatment high-dose Vitamin E, aspirin, anti-inflammatories, antiplatelets, thrombolytics or any other medication that could increase the risk of bleeding.
- •Subject has received any medication which, in the judgement of the investigator, may interfere with the study objectives.
- •Subject has received within the past 12 months or plans to receive during the study any injections outside of those in the study protocol including non-permanent fillers (e.g., hyaluronic acid, CaHA) or neurotoxin on the face below the orbital rim (forehead is acceptable).
- •Subject has received at any time or plans to receive during the study a permanent filler (e.g., polylactic acid, PMMA, silicone) on the face.
- •Subject has received within the past 2 weeks or plans to receive during the study dermal resurfacing procedures or non-invasive skin tightening on the face.
- •Subject has received in the past 2 weeks or plans to receive during the study prescription facial wrinkle therapies (RENOVA), topical steroids, skin irritating topical preparations, or self-tanning agents on the face.
- •Subject has a known history of rapid weight loss/gain or plans to begin a weight loss program during the study (5% of body weight).
结局指标
主要结局
primary effectiveness Wrinkle Severity Rating Scale (WSRS)
时间窗: 6 month
The mean change from baseline of NLFs in the Lumina™ treatment arm will be compared to that of NLFs in the Restylane® Defyne control arm. (5 point scale with 1 being no visible NLF and 5 being extreme, deep and long NLFs)
次要结局
- WSRS other timepoint(6 weeks, 3, 9, and 12 months)
- WSRS proportions(6 weeks, 3, 6, 9, and 12 months)
- GAIS Subject(6 weeks, 3, 6, 9, and 12 months)
- Proportion WSRS photographic(6 weeks, 3, 6, 9, and 12 months)
- Global Aesthetics Improvement Scale (GAIS) - Masked Evaluator(6 weeks, 3, 6, 9, and 12 months)
- GAIS Investigator(6 weeks, 3, 6, 9, and 12 months)
- FACE-Q (standardized questionnaire developed by Memorial Sloan Kettering) Appraisal of Nasolabial Folds Questionnaire(6 weeks, 3, 6, 9, and 12 months)
- Visual Analog Scale (VAS) Pain(injection)
- WSRS Photographics(6 weeks, 3, 6, 9, and 12 months)
研究者
研究点 (4)
Loading locations...
相似试验
暂停
不适用
Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of DepressionDepressive DisorderNCT01794559MYnd Analytics1,922
Unknown
2 期
Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass OpacitiesMultiple Primary Lung CancersNCT04982900Ruijin Hospital138
Unknown
2 期
Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness WoundsWounds and InjuriesNCT02602184Arava Bio Tech Ltd.18
尚未招募
不适用
A Clinical Study to Evaluate the Efficacy and Safety of Monopolar Radiofrequency Combined With SkinCeuticals A.G.E and Skinceuticals CE FERULIC for Improving Facial Skin Elasticity, Tightening and Fading Fine LinesSkin AgingNCT06228833Yes Skin Medical Group50
招募中
不适用
A Clinical Study to Evaluate the Efficacy and Satisfaction of Ultrasound Therapy Combined With SkinCeuticals A.G.E for Improving Facial AgingSkin AgingNCT05748470Yes Skin Medical Group50